Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 3
1999 3
2000 4
2001 1
2002 1
2003 1
2014 4
2015 3
2016 2
2017 6
2018 2
2019 3
2020 3
2021 1
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Eskander RN, et al. Among authors: cantuaria gh. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972022 Free PMC article. Clinical Trial.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.
Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Klopp AH, et al. Among authors: cantuaria ghc. J Clin Oncol. 2018 Aug 20;36(24):2538-2544. doi: 10.1200/JCO.2017.77.4273. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989857 Free PMC article. Clinical Trial.
Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial.
Yeung AR, Deshmukh S, Klopp AH, Gil KM, Wenzel L, Westin SN, Konski AA, Gaffney DK, Small W Jr, Thompson JS, Doncals DE, Cantuaria GHC, D'Souza DP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Yeung AR, et al. Among authors: cantuaria ghc. J Clin Oncol. 2022 Sep 20;40(27):3115-3119. doi: 10.1200/JCO.21.02831. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960897 Free PMC article. Clinical Trial.
Values and worries of ovarian cancer patients.
Pisu M, Kenzik KM, Rim SH, Funkhouser EM, Bevis KS, Alvarez RD, Cantuaria G, Rocconi RP, Martin MY. Pisu M, et al. Among authors: cantuaria g. Gynecol Oncol. 2017 Nov;147(2):433-438. doi: 10.1016/j.ygyno.2017.08.028. Epub 2017 Sep 7. Gynecol Oncol. 2017. PMID: 28888542 Free PMC article.
Epithelial ovarian cancer: An overview.
Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, Franklin G, Ngozi A, Cantuaria G, Singh K, Grizzle W, Landen C, Partridge EE, Rice VM, Reddy ES, Rao VN. Desai A, et al. Among authors: cantuaria g. World J Transl Med. 2014 Apr 12;3(1):1-8. doi: 10.5528/wjtm.v3.i1.1. World J Transl Med. 2014. PMID: 25525571 Free PMC article.
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P. Vergote I, et al. Among authors: cantuaria g. Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28. Eur J Cancer. 2021. PMID: 34597975 Free article. Clinical Trial.
42 results